Skip to main content

The Real-Time Neurotoxicity Analysis of Fe3O4 Nanoparticles Combined with Daunorubicin for Rat Brain In Vivo

Buy Article:

$105.00 plus tax (Refund Policy)

Drug safety for human body should be carefully studied for its potent clinical application. In this report, the neurotoxicity of anticancer drug daunorubicin (DNR) and the oleic acid-capped Fe3O4 nanoparticles (NPs) for rat brain was firstly explored by using the in vivo microdialysis. The results indicated that the anticancer drug DNR itself had the serious neurotoxicity for the rat brain. And this neurotoxicity was influenced through the concentration changes of amino acids. The concentration level of some excitatory amino acids (such as Glu) and some inhibiting amino acid (such as Gly) were considerably decreased while that of the excitatory amino acid Asp was remarkably increased. For the DNR conjugated with Fe3O4 NPs nanocomposites, the side effect of DNR was visibly cut down, and the time to cause the side neurotoxicity was apparently shortened. Thus, it is evident that compared with DNR alone, the DNR conjugated with Fe3O4 NPs nanocomposites have the better biocompatibility and bio-security for the relevant cancer treatment in vitro and in vivo. This raises the promising possibility of the application of these DNR conjugated with Fe3O4 NPs nanocomposites for the target cancer therapy.
No Reference information available - sign in for access.
No Citation information available - sign in for access.
No Supplementary Data.
No Data/Media
No Metrics

Keywords: AMINO ACIDS; DAUNORUBICIN; FE3O4 NANOPARTICLES; MICRODIALYSIS; NEUROTOXICITY

Document Type: Research Article

Publication date: 2012-06-01

More about this publication?
  • Journal of Biomedical Nanotechnology (JBN) is a peer-reviewed multidisciplinary journal providing broad coverage in all research areas focused on the applications of nanotechnology in medicine, drug delivery systems, infectious disease, biomedical sciences, biotechnology, and all other related fields of life sciences.
  • Editorial Board
  • Information for Authors
  • Subscribe to this Title
  • Terms & Conditions
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more